Helix Biopharma Corp HBPCF

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; LDOS007, which is in phase Ib/II for the treatment of lung cancer; and CEACAM6-targeting technology, provides multi-specific antibody-drug conjugates (ADCs) for gastrointestinal cancers and radioligand therapeutics for pancreatic cancer. It has collaboration agreements with Moffitt Cancer Center to investigate and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to investigate the effects of L DOS47 on tumor acidity using imaging technologies. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases; and GEMCEDA, an oral gemcitabine prodrug combined with cedazuridine in preclinical development for the treatment of solid tumors. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.